Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis,Critical Reviews in Oncology/Hematology

当前位置： X-MOL 学术 › Crit. Rev. Oncol. Hematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
Critical Reviews in Oncology/Hematology ( IF 5.5 ) Pub Date : 2021-05-27 , DOI: 10.1016/j.critrevonc.2021.103365
Marco Tagliamento ₁ , Elisa Agostinetto ₂ , Marco Bruzzone ₃ , Marcello Ceppi ₃ , Kamal S Saini ₄ , Evandro de Azambuja ₅ , Kevin Punie ₆ , C Benedikt Westphalen ₇ , Gilberto Morgan ₈ , Paolo Pronzato ₉ , Lucia Del Mastro ₁₀ , Francesca Poggio ₁₁ , Matteo Lambertini ₁₂

Affiliation

Department of Medical Oncology, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy.
Department of Internal Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium; Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy.
Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Covance Inc., Princeton, NJ, USA.
Department of Internal Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Germany.
Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.
Department of Medical Oncology, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy; Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy; Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Background

A systematic review and meta-analysis was performed to estimate mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection.

Methods

A systematic search of PubMed, up to 31 January 2021, identified publications reporting the case-fatality rate (CFR) among adult patients with solid or hematological malignancies and SARS-CoV-2 infection. The CFR, defined as the rate of death in this population, was assessed with a random effect model; 95% confidence intervals (CI) were calculated.

Results

Among 135 selected studies (N = 33,879 patients), the CFR was 25.4% (95% CI 22.9%–28.2%). At a sensitivity analysis including studies with at least 100 patients, the CFR was 21.9% (95% CI 19.1%–25.1%). Among COVID-19 patients with lung (N = 1,135) and breast (N = 1,296) cancers, CFR were 32.4% (95% CI 26.5%–39.6%) and 14.2% (95% CI 9.3%–21.8%), respectively.

Conclusions

Patients with solid or hematological malignancies and SARS-CoV-2 infection have a high probability of mortality, with comparatively higher and lower CFRs in patients with lung and breast cancers, respectively.

中文翻译：

患有实体瘤或血液恶性肿瘤和 SARS-CoV-2 感染的成年患者的死亡率，特别关注肺癌和乳腺癌：系统评价和荟萃分析

背景

进行了系统回顾和荟萃分析，以估计患有实体或血液恶性肿瘤和 SARS-CoV-2 感染的成年患者的死亡率。

方法

对 PubMed 进行的系统检索截至 2021 年 1 月 31 日，发现了报告患有实体瘤或血液恶性肿瘤和 SARS-CoV-2 感染的成年患者病死率 (CFR) 的出版物。CFR 定义为该人群的死亡率，采用随机效应模型进行评估；计算了 95% 置信区间 (CI)。

结果

在 135 项选定研究中（N = 33,879 名患者），病死率为 25.4%（95% CI 22.9%–28.2%）。在一项包括至少 100 名患者的研究的敏感性分析中，CFR 为 21.9%（95% CI 19.1%–25.1%）。在患有肺癌 (N = 1,135) 和乳腺癌 (N = 1,296) 的 COVID-19 患者中，病死率分别为 32.4% (95% CI 26.5%–39.6%) 和 14.2% (95% CI 9.3%–21.8%) 。